Inspire Medical Systems, Inc.
Inspire Medical Systems Announces Q2 2025 Financial Results and Updates Outlook
Summary
Inspire Medical Systems, Inc. reported Q2 2025 financial results, showing an 11% revenue increase to $217.1 million. Despite the increase, the company reported a net loss of $3.6 million due to higher operating expenses and legal fees. The company also announced an executive retirement and updated its full-year 2025 revenue guidance to $900-910 million. Additionally, Inspire will be participating in various investor meetings in August and September 2025.
Profitelligence Alerts
Get alerts for INSP
Be first to know when Inspire Medical Systems, Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Inspire Medical Systems, Inc.
Inspire Medical Systems, Inc. is a pioneering company focused on developing and commercializing innovative medical technology designed to treat obstructive sleep apnea (OSA). The company's flagship product, the Inspire therapy, is an implantable neurostimulation device that provides a unique and effective solution for patients who are unable to utilize traditional continuous positive airway pressure (CPAP) devices. Inspire Medical Systems significantly impacts the healthcare sector by offering a less invasive, patient-friendly alternative to surgical treatments for OSA, improving quality of life for those affected by sleep disorders. Headquartered in Minnesota, Inspire Medical Systems continues to expand its presence within the medical device market, collaborating closely with hospitals and medical professionals to enhance sleep health management globally. This company's contributions underscore a growing focus on personalized and technologically advanced approaches to medical challenges, marking its importance in the evolving landscape of healthcare solutions.
Official SEC Documents
Advertisement